See more : Limitless Earth plc (LME.L) Income Statement Analysis – Financial Results
Complete financial analysis of Third Harmonic Bio, Inc. (THRD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Third Harmonic Bio, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- The Well Told Company Inc. (WLCOF) Income Statement Analysis – Financial Results
- Matinas BioPharma Holdings, Inc. (MTNB) Income Statement Analysis – Financial Results
- Zovio Inc (ZVO) Income Statement Analysis – Financial Results
- Equipements Audiovisuels et Systemes SA (MLEAV.PA) Income Statement Analysis – Financial Results
- Nitro Games Oyj (NITRO.ST) Income Statement Analysis – Financial Results
Third Harmonic Bio, Inc. (THRD)
About Third Harmonic Bio, Inc.
Third Harmonic Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of the medicine for the treatment of allergic and inflammatory diseases. It develops THB001, an oral small-molecule KIT inhibitor for the treatment of chronic urticaria, a dermatologic disease driven by mast cell activation that results in red, itchy, painful welts, or hives, as well as for airway and gastrointestinal tract indications. The company was formerly known as Project IGE, Inc. and changed its name to Third Harmonic Bio, Inc. in June 2019. Third Harmonic Bio, Inc. was founded in 2019 and is headquartered in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 35.00K | 38.00K | 0.00 | 0.00 |
| Gross Profit | -35.00K | -38.00K | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 23.96M | 24.41M | 15.75M | 9.95M |
| General & Administrative | 19.99M | 13.30M | 3.26M | 1.17M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 19.99M | 13.30M | 3.26M | 1.17M |
| Other Expenses | 0.00 | 2.55M | -10.61M | -1.69M |
| Operating Expenses | 43.92M | 37.71M | 19.00M | 11.12M |
| Cost & Expenses | 43.95M | 37.71M | 19.00M | 11.12M |
| Interest Income | 13.13M | 2.55K | 5.00 | 0.00 |
| Interest Expense | 0.00 | 2.55M | 0.00 | 0.00 |
| Depreciation & Amortization | 35.00K | 38.00K | 19.00M | 11.12M |
| EBITDA | -30.79M | -35.12M | -10.61M | -1.69M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -43.95M | -37.71M | -19.00M | -11.12M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 13.13M | 2.55M | -10.61M | -1.69M |
| Income Before Tax | -30.82M | -35.16M | -29.61M | -12.81M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 2.55M | -19.00K | -1.00K |
| Net Income | -30.82M | -37.71M | -29.61M | -12.81M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.78 | -0.96 | -0.77 | -0.33 |
| EPS Diluted | -0.78 | -0.96 | -0.77 | -0.33 |
| Weighted Avg Shares Out | 39.65M | 39.38M | 38.69M | 38.69M |
| Weighted Avg Shares Out (Dil) | 39.65M | 39.38M | 38.69M | 38.69M |
TF FINANCIAL SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe and Powers Taylor LLP Believe the Sale of TF Financial to National Penn May be Unfair to Shareholders
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Announces the Investigation of TF Financial Corporation (THRD) Over the Proposed Sale of the Company to National Penn Bancshares (NPBC)
TF FINANCIAL CORPORATION SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout
National Penn Bancshares, Inc. to Acquire TF Financial Corporation
Source: https://incomestatements.info
Category: Stock Reports